MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT

THE IMPLANTABLE CARDIOVERTER DEFIBRILLATOR ENTERED THE SPECIAL REVIEW PROCEDURE FOR INNOVATIVE MEDICAL DEVICES

This announcement is made by MicroPort CardioFlow Medtech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board of directors (the "**Director(s)**") of the Company (the "**Board**") is pleased to announce that, recently, the Center for Medical Device Evaluation (CMDE) of the National Medical Products Administration ("**NMPA**") has published the Public Notice of the Review Results of Applications for the Special Review Procedure for Innovative Medical Devices (2026 No. 3), which proposed to approve the entry of TILEN/EYLEN, the Group's new-generation implantable cardioverter defibrillator ("**ICD**"), into the special review procedure for innovative medical devices (the "**NMPA Green Path**"). Accordingly, TILEN/EYLEN is expected to be the first domestic MRI-conditional ICD with proprietary intellectual property rights to be approved by the NMPA.

As the core product of the National Key R&D Program of the Ministry of Science and Technology, TILEN/EYLEN is designed to fill the domestic technical gap. Its key technical advantages include:

- **Auto-MRI Function:** significantly reducing patient discomfort caused by non-synchronous modes and simplifying the MRI scanning process;
- **Remote Follow-up:** building a complete solution to enhance patient follow-up compliance based on Bluetooth® Low Energy technology and domestic data centers;
- **Industry-leading Longevity:** effectively reducing infection risks associated with device replacement and easing the long-term economic burden on patients.

Sudden Cardiac Death ("**SCD**") refers to natural death caused by cardiac origins, characterized by a sudden loss of consciousness occurring within one hour of the onset of acute cardiac-related symptoms. It is one of the major causes of death globally. Evidence from multiple large-scale clinical trials has fully confirmed that ICD is currently the most effective measure for preventing SCD, which can restore a normal heart rhythm through tiered therapy, including high-voltage defibrillation, when a patient experiences a life-threatening malignant ventricular arrhythmia (such as ventricular fibrillation or ventricular tachycardia). Our Group's PLATINIUM™ series ICD products received NMPA approval in September 2024, becoming the first domestically produced ICD approved for market, which provides Chinese patients with more options for SCD prevention and treatment, promoting the local development and widespread application of high-energy defibrillation devices in the field of cardiac rhythm management in China. The entry of TILEN/EYLEN in the NMPA Green Path is expected to accelerate the domestic production process of MRI conditional ICDs.

The Company cannot guarantee that TILEN/EYLEN will be ultimately successfully commercialized. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, February 13, 2026

As at the date of this announcement, the executive Directors are Mr. Zhang Ruinian and Mr. Philippe Wanstok, the non-executive Directors are Mr. Chen Guoming, Dr. Brian Chang, Mr. Deng Aoyi and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan.